Rainer Winnenburg1, Alfred Sorbello2, Anna Ripple1, Rave Harpaz3, Joseph Tonning2, Ana Szarfman2, Henry Francis2, Olivier Bodenreider4. 1. Lister Hill National Center for Biomedical Communications, U.S. National Library of Medicine, 8600 Rockville Pike, Bethesda, MD 20894, USA. 2. US Food and Drug Administration, Center for Drug Evaluation and Research, Office of Translational Sciences, 10903 New Hampshire Avenue, Silver Spring, MD 20993, USA. 3. Oracle Health Sciences GBU, 100 Crosby Drive, Bedford, MA 01730, USA. 4. Lister Hill National Center for Biomedical Communications, U.S. National Library of Medicine, 8600 Rockville Pike, Bethesda, MD 20894, USA. Electronic address: olivier.bodenreider@nih.gov.
Abstract
BACKGROUND: Traditional approaches to pharmacovigilance center on the signal detection from spontaneous reports, e.g., the U.S. Food and Drug Administration (FDA) adverse event reporting system (FAERS). In order to enrich the scientific evidence and enhance the detection of emerging adverse drug events that can lead to unintended harmful outcomes, pharmacovigilance activities need to evolve to encompass novel complementary data streams, for example the biomedical literature available through MEDLINE. OBJECTIVES: (1) To review how the characteristics of MEDLINE indexing influence the identification of adverse drug events (ADEs); (2) to leverage this knowledge to inform the design of a system for extracting ADEs from MEDLINE indexing; and (3) to assess the specific contribution of some characteristics of MEDLINE indexing to the performance of this system. METHODS: We analyze the characteristics of MEDLINE indexing. We integrate three specific characteristics into the design of a system for extracting ADEs from MEDLINE indexing. We experimentally assess the specific contribution of these characteristics over a baseline system based on co-occurrence between drug descriptors qualified by adverse effects and disease descriptors qualified by chemically induced. RESULTS: Our system extracted 405,300 ADEs from 366,120 MEDLINE articles. The baseline system accounts for 297,093 ADEs (73%). 85,318 ADEs (21%) can be extracted only after integrating specific pre-coordinated MeSH descriptors and additional qualifiers. 22,889 ADEs (6%) can be extracted only after considering indirect links between the drug of interest and the descriptor that bears the ADE context. CONCLUSIONS: In this paper, we demonstrate significant improvement over a baseline approach to identifying ADEs from MEDLINE indexing, which mitigates some of the inherent limitations of MEDLINE indexing for pharmacovigilance. ADEs extracted from MEDLINE indexing are complementary to, not a replacement for, other sources. Published by Elsevier Inc.
BACKGROUND: Traditional approaches to pharmacovigilance center on the signal detection from spontaneous reports, e.g., the U.S. Food and Drug Administration (FDA) adverse event reporting system (FAERS). In order to enrich the scientific evidence and enhance the detection of emerging adverse drug events that can lead to unintended harmful outcomes, pharmacovigilance activities need to evolve to encompass novel complementary data streams, for example the biomedical literature available through MEDLINE. OBJECTIVES: (1) To review how the characteristics of MEDLINE indexing influence the identification of adverse drug events (ADEs); (2) to leverage this knowledge to inform the design of a system for extracting ADEs from MEDLINE indexing; and (3) to assess the specific contribution of some characteristics of MEDLINE indexing to the performance of this system. METHODS: We analyze the characteristics of MEDLINE indexing. We integrate three specific characteristics into the design of a system for extracting ADEs from MEDLINE indexing. We experimentally assess the specific contribution of these characteristics over a baseline system based on co-occurrence between drug descriptors qualified by adverse effects and disease descriptors qualified by chemically induced. RESULTS: Our system extracted 405,300 ADEs from 366,120 MEDLINE articles. The baseline system accounts for 297,093 ADEs (73%). 85,318 ADEs (21%) can be extracted only after integrating specific pre-coordinated MeSH descriptors and additional qualifiers. 22,889 ADEs (6%) can be extracted only after considering indirect links between the drug of interest and the descriptor that bears the ADE context. CONCLUSIONS: In this paper, we demonstrate significant improvement over a baseline approach to identifying ADEs from MEDLINE indexing, which mitigates some of the inherent limitations of MEDLINE indexing for pharmacovigilance. ADEs extracted from MEDLINE indexing are complementary to, not a replacement for, other sources. Published by Elsevier Inc.
Entities:
Keywords:
Adverse drug events; MEDLINE indexing; Pharmacovigilance
Authors: Rave Harpaz; Alison Callahan; Suzanne Tamang; Yen Low; David Odgers; Sam Finlayson; Kenneth Jung; Paea LePendu; Nigam H Shah Journal: Drug Saf Date: 2014-10 Impact factor: 5.606
Authors: Paul Avillach; Jean-Charles Dufour; Gayo Diallo; Francesco Salvo; Michel Joubert; Frantz Thiessard; Fleur Mougin; Gianluca Trifirò; Annie Fourrier-Réglat; Antoine Pariente; Marius Fieschi Journal: J Am Med Inform Assoc Date: 2012-11-29 Impact factor: 4.497
Authors: Rebecca Mary Diane Smyth; Elizabeth Gargon; Jamie Kirkham; Lynne Cresswell; Su Golder; Rosalind Smyth; Paula Williamson Journal: PLoS One Date: 2012-03-05 Impact factor: 3.240
Authors: Dina Demner-Fushman; James G Mork; Willie J Rogers; Sonya E Shooshan; Laritza Rodriguez; Alan R Aronson Journal: AMIA Annu Symp Proc Date: 2018-12-05
Authors: Juan M Banda; Lee Evans; Rami S Vanguri; Nicholas P Tatonetti; Patrick B Ryan; Nigam H Shah Journal: Sci Data Date: 2016-05-10 Impact factor: 6.444
Authors: François Pognan; Thomas Steger-Hartmann; Carlos Díaz; Niklas Blomberg; Frank Bringezu; Katharine Briggs; Giulia Callegaro; Salvador Capella-Gutierrez; Emilio Centeno; Javier Corvi; Philip Drew; William C Drewe; José M Fernández; Laura I Furlong; Emre Guney; Jan A Kors; Miguel Angel Mayer; Manuel Pastor; Janet Piñero; Juan Manuel Ramírez-Anguita; Francesco Ronzano; Philip Rowell; Josep Saüch-Pitarch; Alfonso Valencia; Bob van de Water; Johan van der Lei; Erik van Mulligen; Ferran Sanz Journal: Pharmaceuticals (Basel) Date: 2021-03-08